PL4171571T3 - Pochodne tetrazolu jako inhibitory trpa1 - Google Patents

Pochodne tetrazolu jako inhibitory trpa1

Info

Publication number
PL4171571T3
PL4171571T3 PL21735302.8T PL21735302T PL4171571T3 PL 4171571 T3 PL4171571 T3 PL 4171571T3 PL 21735302 T PL21735302 T PL 21735302T PL 4171571 T3 PL4171571 T3 PL 4171571T3
Authority
PL
Poland
Prior art keywords
tetrazole derivatives
trpa1 inhibitors
trpa1
inhibitors
tetrazole
Prior art date
Application number
PL21735302.8T
Other languages
English (en)
Inventor
Martin Thomas Fleck
Florian Paul Christian Binder
Jens Willwacher
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of PL4171571T3 publication Critical patent/PL4171571T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
PL21735302.8T 2020-06-29 2021-06-25 Pochodne tetrazolu jako inhibitory trpa1 PL4171571T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20182987 2020-06-29
PCT/EP2021/067467 WO2022002780A1 (en) 2020-06-29 2021-06-25 Tetrazole derivatives as trpa1 inhibitors

Publications (1)

Publication Number Publication Date
PL4171571T3 true PL4171571T3 (pl) 2025-03-03

Family

ID=71401655

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21735302.8T PL4171571T3 (pl) 2020-06-29 2021-06-25 Pochodne tetrazolu jako inhibitory trpa1

Country Status (32)

Country Link
US (2) US11891403B2 (pl)
EP (1) EP4171571B1 (pl)
JP (1) JP7539500B2 (pl)
KR (1) KR20230028546A (pl)
CN (3) CN121270577A (pl)
AR (1) AR122778A1 (pl)
AU (1) AU2021301140A1 (pl)
BR (1) BR112022021386A2 (pl)
CA (1) CA3182143A1 (pl)
CL (1) CL2022003325A1 (pl)
CO (1) CO2022016762A2 (pl)
CR (1) CR20220668A (pl)
DK (1) DK4171571T3 (pl)
DO (1) DOP2022000270A (pl)
EC (1) ECSP22088958A (pl)
ES (1) ES3005209T3 (pl)
FI (1) FI4171571T3 (pl)
HR (1) HRP20241730T2 (pl)
HU (1) HUE069955T2 (pl)
IL (1) IL299172B2 (pl)
JO (1) JOP20220356B1 (pl)
LT (1) LT4171571T (pl)
MA (1) MA60099B1 (pl)
MX (1) MX2022016272A (pl)
PE (1) PE20240594A1 (pl)
PH (1) PH12022553493A1 (pl)
PL (1) PL4171571T3 (pl)
PT (1) PT4171571T (pl)
RS (1) RS66140B1 (pl)
SA (1) SA522441973B1 (pl)
SI (1) SI4171571T1 (pl)
WO (1) WO2022002780A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022258653A1 (en) 2021-04-14 2023-08-17 Boehringer Ingelheim International Gmbh 3h,4h,5h,6h,7h-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as trpa1 inhibitors
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2392328A1 (en) * 2005-05-09 2011-12-07 Hydra Biosciences, Inc. Compounds for modulating TRPV3 Function
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2018096159A1 (en) 2016-11-28 2018-05-31 F. Hoffmann-La Roche Ag Oxadiazolones as transient receptor potential channel inhibitors
AU2022258653A1 (en) 2021-04-14 2023-08-17 Boehringer Ingelheim International Gmbh 3h,4h,5h,6h,7h-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as trpa1 inhibitors

Also Published As

Publication number Publication date
SA522441973B1 (ar) 2024-07-21
CL2022003325A1 (es) 2023-03-31
MX2022016272A (es) 2023-02-09
ES3005209T3 (en) 2025-03-14
WO2022002780A1 (en) 2022-01-06
RS66140B1 (sr) 2024-11-29
JP7539500B2 (ja) 2024-08-23
IL299172A (en) 2023-02-01
CN121319001A (zh) 2026-01-13
JP2023533189A (ja) 2023-08-02
US20240352033A1 (en) 2024-10-24
KR20230028546A (ko) 2023-02-28
AR122778A1 (es) 2022-10-05
BR112022021386A2 (pt) 2023-01-10
CN116157130A (zh) 2023-05-23
HUE069955T2 (hu) 2025-04-28
EP4171571B1 (en) 2024-10-30
CN116157130B9 (zh) 2025-12-05
LT4171571T (lt) 2024-11-25
IL299172B2 (en) 2026-03-01
HRP20241730T2 (hr) 2025-04-25
ECSP22088958A (es) 2022-12-30
MA60099B1 (fr) 2024-11-29
PE20240594A1 (es) 2024-03-21
CN116157130B (zh) 2025-11-14
SI4171571T1 (sl) 2025-03-31
CA3182143A1 (en) 2022-01-06
PH12022553493A1 (en) 2024-04-22
JOP20220356B1 (ar) 2024-12-22
DOP2022000270A (es) 2023-01-15
CN121270577A (zh) 2026-01-06
TW202216729A (zh) 2022-05-01
CO2022016762A2 (es) 2022-12-09
CR20220668A (es) 2023-03-10
DK4171571T3 (da) 2025-01-20
NZ793327A (en) 2025-02-28
HRP20241730T1 (hr) 2025-02-28
US20210403482A1 (en) 2021-12-30
IL299172B1 (en) 2025-11-01
FI4171571T3 (fi) 2024-12-02
US11891403B2 (en) 2024-02-06
EP4171571A1 (en) 2023-05-03
AU2021301140A1 (en) 2022-11-10
PT4171571T (pt) 2024-12-04

Similar Documents

Publication Publication Date Title
IL277455A (en) History of aminopyrimidines as CTPS1 inhibitors
EP3720495A4 (en) HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS
IL307448A (en) Phosphorus derivatives as novel inhibitors of SOS1
IL286363A (en) Benzodiazepine derivatives as rsv inhibitors
IL310403A (en) Converted pyridine derivatives as SARM1 inhibitors
IL273579A (en) Salts of pyrrolothrizine compounds used as tem inhibitors.
HUE070004T2 (hu) Tetrazol-származékok, mint TRPA1 inhibitorok
IL292093A (en) Thianopyrimidones as trpa1 inhibitors
IL306065A (en) Uracil history as TRPA1 inhibitors
IL309013A (en) Converted pyrimidinylpyrazoles as CDK2 inhibitors
IL319011A (en) Triazinone derivatives as NLRP3 inhibitors
PH12022550298A1 (en) Quinoline derivatives as protein kinase inhibitors
IL319009A (en) Triazinone derivatives as NLRP3 inhibitors
IL292095A (en) Thianopyrimidones as trpa1 inhibitors
LT4171563T (lt) Tetrazolo ddariniai kaip trpa1 inhibitoriai
HUE069955T2 (hu) Tetrazol származékok, mint TRPA1 inhibitorok
EP4029853A4 (en) SYNTHETIC METHOD APPLIED TO A HETEROCYCLIC INTERMEDIATE OF KRAS INHIBITOR DRUGS
IL314297A (en) N3-substituted URACIL compounds as TRPA1 inhibitors
IL288472A (en) Tetracyclic compounds as cdc7 inhibitors
EP3976038A4 (en) HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS
SG11202006394YA (en) Benzotriazole derivatives as corrosion inhibitors
IL310025A (en) Heterocyclic compounds as MAP4K1 inhibitors
ZA202100140B (en) Pyridopyrimidinone derivatives for use as axl inhibitors